Global cancer 5 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers 6 in 185 countries, CA Cancer J Clin. nov, vol.68, issue.6, pp.394-424, 2018. ,
,
, Carcinoma of the ovary
, Gynecological Cancer. Int J Gynaecol Obstet, vol.95, issue.1, pp.161-92, 2006.
Staging classification for cancer 11 of the ovary, fallopian tube, and peritoneum, Int J Gynaecol Obstet. janv, vol.124, issue.1, pp.1-5, 2014. ,
,
, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J
, , vol.363, pp.943-53, 2010.
Role 16 of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and 17 tubal cancer: Surgical and oncological outcomes ,
, Oncol, vol.119, issue.2, pp.259-64, 2010.
, European Society of Gynaecological Oncology. Ovarian Cancer Surgery Guidelines, p.20
, Advanced stage. guidelines.esgo.org, 2016.
Primary 12 chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer 13 (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet. 18 juill, vol.14, issue.9990, pp.249-57, 2015. ,
Phase 16 III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in 17 advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis 18 of peri-operative outcome, Eur J Cancer, vol.59, pp.22-33, 2016. ,
Complete cytoreductive surgery is feasible and 20 maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study ,
, Gynecol Oncol. mai, vol.69, issue.2, pp.103-111, 1998.
Survival effect of 23 maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a 24 meta-analysis, J Clin Oncol. 1 mars, vol.20, issue.5, pp.1248-59, 2002. ,
Only 2 complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal 3 debulking in advanced ovarian cancer, Eur J Obstet Gynecol Reprod Biol. déc, vol.4, pp.100-105, 2017. ,
Omental 6 chemotherapy effects as a prognostic factor in ovarian cancer patients treated with 7 neoadjuvant chemotherapy and delayed primary surgical debulking, Ann Surg Oncol. sept, vol.8, issue.9, pp.2649-53, 2007. ,
Impact of residual disease on overall survival 10 in patients with FIGO stage IIIB-IIIC vs. stage IV epithelial ovarian cancer after primary 11 surgery, Acta Obstet Gynecol Scand. 31 août, 2018. ,
Impact of increased 13 utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: 14 experience from a comprehensive cancer center, Journal of Gynecologic Oncology ,
, , vol.29, p.23
Primary surgery or 18 neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian 19 cancer, Eur J Cancer. sept, vol.47, issue.3, pp.88-92, 2011. ,
Surgery for advanced epithelial ovarian cancer, Best Pract Res, vol.21 ,
, Clin Obstet Gynaecol. mai, vol.41, pp.71-87, 2017.
Disease 23 Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall 24 ,
Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology 25 Group study, Gynecol Oncol. déc, vol.143, issue.3, pp.511-516, 2016. ,
, Development and internal validation of a prognostic model for survival after debulking 28 surgery for epithelial ovarian cancer, Gynecol Oncol, vol.135, issue.1, pp.13-21, 2014.
The Impact of Percent Reduction in CA ,
, Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and 2 endometrioid ovarian carcinomas, Cancer Res. 15 mars, vol.65, issue.6, pp.2162-2171, 2005.
Could HE4 level 4 measurements during first-line chemotherapy predict response to treatment among ovarian 5 cancer patients?, PLoS ONE, vol.13, issue.3, p.194270, 2018. ,
Prognostic value of HE4 in patients with ovarian 7 cancer, Clin Chem Lab Med. 27 juin, vol.56, issue.7, pp.1026-1060, 2018. ,
Ovarian 9 cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and 10 survival, Ecancermedicalscience, vol.10, p.639, 2016. ,
Long-term ovarian 12 cancer survival associated with mutation in BRCA1 or BRCA2, J Natl Cancer Inst. 16 janv, vol.13, issue.2, p.15, 2013. ,
High response rates to neoadjuvant platinum-based therapy in ovarian 16 cancer patients carrying germ-line BRCA mutation, Cancer Lett. 28 déc, vol.369, issue.2, pp.363-370, 2015. ,
,
, Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian 19
, Carcinoma by Angiogenesis-related Genes, Anticancer Res. sept, vol.38, issue.9, pp.5393-400, 2018.